SNMMI calls on CMS to cover PET agent Amyvid

02/3/2013 | DOTMed.com

SNMMI and other supporters of the PET imaging agent Amyvid are calling on CMS to provide coverage of the agent for diagnosis of Alzheimer's disease. The move follows a Medicare Evidence Development and Coverage Advisory Committee hearing where the panel questioned the utility of Amyvid in improving health outcomes. SNMMI said clinical evidence and FDA approval of the agent back "the ability of beta-amyloid imaging to change patient management, leading to better outcomes for patients."

View Full Article in:

DOTMed.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
White Plains, NY
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ